DTx WEST 2022

YiDing Yu, MD, is an international keynote speaker, a Harvard physician, published researcher, and a serial entrepreneur in healthcare AI and digital tech. She is Chief Medical Officer of Verata Health, a venture-backed AI company that automates prior authorizations for providers and payers. 

Verata Health is used by thousands of physicians to automate prior authorizations for advanced imaging, surgeries and procedures, and specialty drugs, dramatically reducing staff burnout and streamlining the revenue cycle.

As a serial entrepreneur, Dr. Yu was honored by the Cartier Women’s Initiative Awards as woman entrepreneur of the year in 2018. She has won top innovation prizes from the American Heart Association, the American Medical Association, and the Cleveland Clinic for her ground-breaking work. Previously, Dr. Yu served as Chief Innovation Engineer of Atrius Health, a $2B multispecialty practice in Boston, MA.

In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.

Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve.

Mike leads Market Access, Value & Evidence on behalf of Pear Therapeutics. Prior to joining Pear, he was a Divisional Principal with ICON plc, where he led the firm’s Value Strategy Consulting practice and Global Pricing & Market Access team in the US and Europe. In previous roles with EMD Serono, Sanofi, Allergan, OM1, and Beansprout Networks, Mike orchestrated strategy and led commercial functions including business development, product development and commercialization strategy, market access and reimbursement strategy, payer and specialty account management, contracts and pricing, operations and analytics, sales, sales training and leadership development.

Mike led a team that conceived and launched the hallmark biotech industry reference, EMD Serono Specialty Digest™, in addition to pioneering the implementation of the first ever outcomes-based agreements for a specialty biologic with a health plan, and then with a PBM, in the United States. Subsequently, Mike has actualized dozens of outcomes and value-based payer arrangements between digital health, biopharma, payer and technology value chain stakeholders. He has been a leading innovator, global advisor, author, thought leader and trusted catalyst in the field since 2009, orchestrating market access and innovative go-to-market models for some of the world’s most cutting-edge technologies and novel therapeutics.

Mike earned his BSBA in Finance and Banking from the University of Missouri-Columbia, where he was a distance freestyler and Co-Captain of the Men’s Swimming Team, and his MBA in Entrepreneurship and Marketing from the FW Olin Graduate School of Business at Babson College.

Adam is Director of Clinical Operations at Curebase, overseeing all Curebase’s clinical trials, including digital therapeutics. Adam has a range of therapeutic and research experience. He began his career as a coordinator and transitioned into monitoring and project management roles of increasing responsibility within CROs, academia, and pharma.

Adam received a master’s in clinical research from George Washington University and is active in his professional community.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Dr. Jin Lee is the Director of Digital Health Product/ Commercial Strategy at Astellas pharma. She was formerly at the innovation centers and venture arms of Humana, 4th largest health insurance company, and Providence St. Joseph Health, 3rd largest nonprofit hospital system, focused on series A & B digital health investments and pilots. Dr. Lee also cofounded and worked in multiple startups in maternal/child health, radiology, and education. Based in San Francisco, she advises multiple digital health startups and accelerator programs. Dr. Lee received her Ph.D in neuropsychology from the University of Oxford and BA in biology and neuroscience from the University of Pennsylvania.

Dr. Maroof Ahmed is a medical doctor who graduated from Imperial College London with dual degrees in Medicine and Business Management. He is the co-founder and COO of Digital Therapeutics.

Maroof spent 4 years conducting academic research in the fields of neurology, behavioural change, digital health and smoking cessation. He has published multiple peer-reviews papers on these topics and also acts as a reviewer for JMIR.

Whilst training to become a doctor, Maroof saw the impact smoking had on the lives of the patients around him and wanted to make a difference. So together with his co-founders, they put on hold their clinical careers to pursue Quit Genius full-time. This was a tough decision but they made this choice as it will allow them to make an impact on the lives of people worldwide at scale.

Juliette McClendon, PhD is an Assistant Professor in the Department of Psychiatry at Boston University School of Medicine. Dr. McClendon’s research focuses on the contributions of race-related stressors such as discrimination to racial/ethnic minority’s mental health, as well as treatment seeking, engagement, and satisfaction.

Kate Smith has 10 years of experience in digital health innovation spanning patient, provider, and employer solutions. In her current role as Sr. Director of Product, Kate leads new product development in the strategic areas of population health, DTx and condition management.

Brent Vaughan is CEO of Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease. With more than 20 years of experience, he has a proven track record of success developing proprietary technologies and products across multiple domains, including digital therapeutics, medical devices and pharmaceuticals.

Prior to Cognito, Brent was Chief Executive Officer and Co-Founder at Cognoa, an AI-based digital therapeutics company, where he established the company as a leader in digital therapeutics and pediatric behavioral health. Under his leadership, Cognoa was awarded FDA Breakthrough Designation for the first two products for autism and successfully completed the clinical development of the lead product. He was also co-founder at WellnessFX, a leading digital health company.

Brent has also held leadership positions in business development and product management in therapeutic and medical device companies including Saegis Pharmaceuticals, Nektar Therapeutics, and Roche. He received his M.B.A. from Santa Clara University and a B.S. in Biochemistry from the University of California, Davis.

Corey joined the HTA in January 2019 as Vice President of Strategic Business Initiatives, focusing on optimizing specialty pharmacy spend, direct to manufacturer and other clinically opportunities for HTA members. Corey has approximately twenty years of managed care pharmacy experience focused on specialty pharmacy, pharmacy benefit management, drug manufacturing and consulting for large and jumbo employers. In addition, Corey has held various leadership roles in business development, clinical services, and consulting for Express Scripts/CuraScript, The Burchfield Group, Artemetrx, Archimedes and Genentech prior to joining the HTA. ​

Dr. Belken holds a Doctorate of Pharmacy degree from The University of Minnesota, where he continues to be involved as an instructor and preceptor and a Bachelor’s of Science from Wartburg College. He resides in Prior Lake, Minnesota with his wife, Karla, and their two kids Josie (12) and Bryce (8).

Maria Harrison, Senior Vice President, Decentralized Clinical Trial Operations and Real World Solutions, has over 30 years of experience in managing all aspects of drug and device development in both the pharmaceutical and CRO industries. Prior to joining PRA, Ms Harrison was the Vice President of Operations in North America for clinical and post-approval services at a large CRO, where she had overall responsibility for all operational aspects of over 100 projects. Throughout her career, she has managed numerous clinical studies of various sizes on a global basis, across all clinical phases, and in multiple therapeutic indications. Specifically in the last 10 years, she has been responsible for overseeing global real world/post-approval research in the areas of product registries, disease registries, risk management programs (including risk evaluation and mitigation strategies [REMS] and European Union risk management plans), post-authorization safety studies, minimal risk diagnostic biomarker studies, retrospective chart review studies, and other real world evidence studies. These studies cover multiple indications and all services from protocol development through manuscript publication. They range from small investigator-initiated studies to large, global registries inclusive of over 10,000 patients, 500 sites, and 30+ countries. Ms Harrison has held numerous positions within clinical monitoring, project management, line management, and business development, and she has also served as the business unit leader for RWS. She is a notable industry speaker and chairperson at many global medical affairs conferences on topics specific to real world and post-approval research

Gary M. Smithson, MD, MBA, is a board-certified pediatrician and accomplished healthcare executive. He brings more than 35 years of business and clinical experience on the executive team at a population health management company and as a healthcare consultant.

His areas of expertise include wellbeing and disease management programs, onsite and near-site health services, high-performance provider networks, cost and quality transparency, telehealth, consumer healthcare navigation, employer-sponsored health benefits and health plan clinical operations.

Joris van Dam is a Digital Health intrapreneur with 15 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of therapies in schizophrenia and multiple sclerosis.

Prior to that, Joris launched a number of digital health innovation initiatives at Novartis, including the launch of the Trials of the Future program, the Patients-2-Trials Consortium (a pharma consortium project to facilitate clinical research navigation for patients), the Clinical Research Collaboration with Walgreens (running interventional clinical trials at local Walgreens Healthcare clinics), TriNetX (a platform for using electronic medical records for study planning and design), CentrosHealth (a platform for patient engagement Apps in clinical trials), and a mobile platform for bedside data collection for clinical trials in Africa.

Prior to joining Novartis, Joris spent 7 years at Janssen, where a.o. he worked in partnership with the Bill and Melinda Gates Foundation to launch a mobile health platform for improving treatment of HIV patients in various regions across India, and led Janssen’s participation to the EHR4CR program at the EU’s Innovative Medicines Initiative (IMI). Prior to joining pharmaceutical research and development, Joris spent 7 years in consulting across industries and across Europe. Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

Dr. Carl is a clinical psychologist who specializes in the research and treatment of anxiety, depression, insomnia, and related disorders in adults. She has authored numerous peer-reviewed publications, and has presented her research and clinical trainings at leading national and international conferences, such as the Association for Behavioral and Cognitive Therapies, World Congress for Behavioral and Cognitive Therapies, and the American Psychological Association (APA). She currently serves Chair of the APA’s Division 12 Presidential Task Force for integration of technology and treatment.

As the VP of Clinical Development & Medical Affairs for Big Health, Dr. Carl is responsible for developing evidence-based digital therapeutics for common mental health conditions that can be implemented within large employers and health systems. She obtained her PhD in clinical psychology from Boston University, with training in the Center for Anxiety and Related Disorders at Boston University, Massachusetts General Hospital/Harvard Medical School, and the VA Health System’s National Center for Innovation to Implementation.

Susan Baumgartner offers a unique balance of clinical and business expertise with 25 years of experience in the pharmaceutical and digital health industries. She is currently the VP of Product Management & Regulatory Affairs at etectRx. Susan began her career with Merck & Co. and served in numerous leadership roles in marketing, sales, commercial operations, medical strategies and strategic planning. She also held key executive positions within technology startups with a focus on improving medication use and enhancing therapeutic outcomes. Susan earned a Doctor of Pharmacy and MBA degrees with highest honors from the University of Florida. She is an accomplished business executive with expertise in the successful development and commercialization of pharmaceutical products, medical devices and digital health solutions.

Elan is a Principal with JAZZ Venture Partners, focusing on healthcare and participates on boards in the space. JAZZ is a traditional venture capital firm typically leading or co-leading late seed through series B rounds. Previously Elan founded and grew several startups as an operator and adviser across digital health, neuroscience, and AI, including co-founding digital therapeutics companies Swing Therapeutics and Blue Note Therapeutics. Other past experiences include consulting for larger health institutions with the Boston Consulting Group and Monitor Deloitte. He received his bachelor’s degree from Tufts University and his MBA from the University of California, Berkeley.

Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Prior to joining Big Health, Ankur led regulatory affairs activities for next generation sequencing based oncology diagnostics at Roche. Ankur has also previously served in regulatory affairs and quality systems roles at Abbott Laboratories, Medtronic and Johnson & Johnson. Ankur received his Master’s degree in Biomedical Engineering from the University of Southern California, Los Angeles.

Dr. Isaac Rodriguez-Chavez is a biomedical leader with expertise in Virology, Microbiology, Immunology, Vaccinology, and Viral Oncology.  His expertise spans basic, translational, pre-clinical and clinical research (phase I – IV global trials).  He also has expertise in digital health technologies, clinical research development and operations, regulatory affairs, approval or licensure of medical products, and quality control and quality assurance. 

Dr. Rodriguez-Chavez joined PRA Health Sciences as a Senior Vice President for Scientific and Clinical Affairs, leading the Strategy of PRA’s Global Center of Excellence for Decentralized Clinical Trials (DCTs) using Digital Health Technologies (DHTs). He also has other executive leadership roles across the organization that deal with scientific and medical affairs.  

Overall, Dr. Rodriguez-Chavez has over 32 years of work experience in several national and international organizations, including the U.S. Food and Drug Administration (FDA), National Institute of Health (NIH), industry and non-profit research organizations.  Recently, he worked at the FDA, Center for Drug Evaluation and Research (CDER) as a Senior Officer for Clinical Research Methodologies, Regulatory Compliance and Medical Policy Development.  He led FDA work on DCTs using DHTs, and he was directly involved in programs for the modernization of clinical research that impact multiple disease areas.  

Other past positions he held included CEO and Founder of a biomedical consulting firm, 4Biosolutions Consulting; Vice President for Research, Texas Biomedical Research Institute; Director of the AIDS and Immunosuppression Program, National Institute of Dental and Craniofacial Research (NIDCR), NIH; Senior Clinical Scientist, Schering Plough Corporation; Director of Portfolio for HIV Vaccine Programs, National Institute of Allergy and Infectious Diseases (NIAID), NIH; Scientist at St. Luke’s/Roosevelt Hospital, Columbia University; Lead Scientist, Polar Biotechnology Company (Venezuela); and Scientist in Viral Immunology, Venezuelan Institute for Scientific Research, IVIC.

He issued the first U.S. Good Clinical Laboratory Practice (GCLP) Guidelines to improve the consistency of clinical laboratory endpoints supporting trials globally, published numerous scientific and technical articles, and has been an invited speaker in 80 global conferences.  He has a B.S. in Biology (Venezuela), M.S. in Microbiology (Venezuela), M.H.S. in Clinical Research (Duke School of Medicine), and a Ph.D. in Virology and Immunology (University of Delaware).  He did two post-doctoral trainings in Viral Immunology and Viral Oncology at the National Institute on Aging (NIA) and the National Cancer Institute (NCI) at NIH.   

Dr. Rodriguez-Chavez is a Board Member of the Scientific Leadership of the Digital Medical Society (DiME).  He is also a leadership member of the Research Committee of DiME.  He is a regulatory Advisor of the Institute of Electrical and Electronics Engineers (IEEE) fostering initiatives on DCTs and DHTs.  He is a Leadership Council member of the Decentralized Trials & Research Alliance (DTRA) and he is a board member of the Hypertrophic Cardiomyopathy Association (HCMA).  He is a global content editor for regulatory science at the DIA Global Forum magazine.  He is also an active member is fourteen professional associations, including the American Association of Immunologists, American Society for Virology, American Society of Microbiology, Society of Quality Assurance, Association of Clinical Research Professionals, New York Academy of Sciences, International AIDS Society, International Association for Dental Research, American Association for Dental Research, and Regulatory Affairs Professional Society. 

Jordan Silberman, MD, PhD is Director of Clinical Analytics and Research on Anthem’s Digital Care Delivery team. He leads scientific and statistical strategy for digital health initiatives, implements digital disease management solutions, and champions evidence-based approaches to digital health innovation. Jordan has more than a decade of experience in digital health and previously served as Head of Clinical Programs and Outcomes Research at Vida Health. His interests include adapting rigorous health economics and outcomes research (HEOR) methods to evaluate digital health interventions, evidence standards for digital health technologies, statistical analysis in digital health, scalable approaches to health behavior change, and health literacy. Jordan earned an MD (honors in research), a PhD (psychology), and a certificate in statistics from the University of Rochester, as well as a master’s degree in psychology from the University of Pennsylvania.

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas.  Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business.  In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device.  Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business.  She received an MSc from Waseda University and an MBA from Tsukuba University.

Dr. Andrey Ostrovsky was the former Chief Medical Officer of the US Medicaid program. He is the Managing Partner at Social Innovation Ventures where he invests in and advises companies and non-profits dedicated to eliminating disparities. He also advises federal and state regulators on how to incorporate human centered design into policy making. He previously operated a series of methadone clinics in Baltimore, Maryland. Prior to working on the front line of the opioid use disorder crisis, he served as the Chief Medical Officer for the Center for Medicaid and CHIP Services, the nation’s largest health insurer, where he advocated to protect the program against several legislative efforts to significantly dismantle the program. He also led efforts to streamline Medicaid and make it more customer-centric. Before leading the Medicaid program, he co-founded the software company, Care at Hand, an evidence-based predictive analytics platform that used insights of non-medical staff to prevent aging people from being hospitalized. Care at Hand was acquired in 2016 by Mindoula Health. Before Care at Hand, Dr. Ostrovsky led teams at the World Health Organization, United States Senate, and San Francisco Health Department toward health system strengthening. Dr. Ostrovsky has served on several boards and committees dedicated to behavioral health, interoperability standards, quality measurement, and home and community based services including the National Academies of Medicine, National Quality Forum, Institute for Healthcare Improvement, and the Commonwealth Fund.

Andrey holds a Medical Doctorate and undergraduate degrees in Chemistry and Psychology Magna cum Laude from Boston University and is a member of Phi Beta Kappa. Andrey completed his pediatrics residency training in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital where he was a clinical instructor at Harvard Medical School. He is currently teaching faculty and attending physician at Children’s National Medical Center.

Brian Dolan is the founder and lead writer of the digital health market research site Exits & Outcomes. You might know him from his last startup, MobiHealthNews, which started up in 2008 and sold to HIMSS in 2015. Exits & Outcomes offers subscribers three newsletters focused on health tech funding (Mondays), employer/enrollment-based digital health companies (Wednesdays), and pharma-focused or FDA-regulated digital health (Fridays). E&O also publishes long-form research reports that dig into the strategies of individual companies including UnitedHealth Group, Omada Health, Pear Therapeutics, Hinge Health, and more.

Dr. Liz Kwo is an experienced healthcare executive with 15+ years specialized in building and scaling digital healthcare products to provide high quality care, leveraging predictive and prescriptive analytics to improve outcomes. Her current role at Anthem is to create digitized, automated, and continuously improved frictionless patient and provider experience that drives down cost of care. She has worked in remote patient monitoring for Medtronic, American Well as the VP of Provider Networks for telehealth, and is an active angel investor in the healthcare community, with a specific interest in technology-enabled healthcare delivery such as RubiconMD. She founded multiple venture-backed companies in educational technology (sold to CVC private equity firm in 2014), digital healthcare, and healthcare supplies and is passionate about creating seamless tailored experiences for enrolling patients and building on-demand data driven insights to support national employer clients.

Dr. Kwo has extensive experience in healthcare technology product development and commercialization, P&L, B2B/B2C marketing & sales, strategic partnerships, & post-merger integration. A practicing physician in urgent and preventive care, Dr. Kwo’s clinical expertise allows her to translate ideas from bench to bedside. She is also a lecturer in the Harvard-MIT HST Program and an Instructor of Medicine at Harvard Medical School.

Dr. Kwo has an MD from Harvard Medical School, MBA from Harvard Business School, MPH from Harvard TH Chan School of Public Health, and a BA from Stanford University. She completed her residency at Harvard Preventive Care and is Board Certified in Preventive Care and Occupational Medicine.

Lucia Savage is a nationally-recognized thought leader on health information privacy and HIPAA. Using strategic advice to advance digital technology to deliver health care while protecting privacy, she drives Omada Health’s continued commitment to advancing digital health, including the safe, secure, and effective handling of participants’ personal health information. Prior to joining Omada, she served the Obama Administration as Chief Privacy Officer at the U. S. Department of Health and Human Services Office of the National Coordinator for Health IT. She first implemented HIPAA for Stanford University in 2000, and later oversaw the HIPAA compliance and data strategy for California’s pre-ACA health insurance exchange, PacAdvantage, where she served as General Counsel. In addition to her work at Omada, Lucia serves as Vice-Chair and Chair-Elect of the Committee on Advocacy and Public Policy at Academy Health.  Lucia has a B.A. with Honor from Mills College and received her Juris Doctor summa cum laude from New York University School of Law.

Dr. Marisa Cruz is the Chief Medical Officer for Limbix. She previously served as the Senior Medical Advisor for the Digital Health Unit in the Center for Devices and Radiological Health at the US Food and Drug Administration, providing leadership in the development and implementation of digital health policy for medical devices. Prior to joining CDRH, Marisa served as a senior advisor to the Associate Commissioner for Public Health Strategy and Analysis. She received her M.D. from the Johns Hopkins School of Medicine, completed an Internal Medicine residency and Endocrinology fellowship at the University of California, San Francisco, and continues to provide clinical care at George Washington University.

Dr. Krystal is the Ray and Dagmar Dolby Distinguished Professor in the Departments of Psychiatry and Neurology, Vice-Chair for Research in the Department of Psychiatry, Director of the Dolby Family Center for Mood Disorders, Director of the UCSF Interventional Psychiatry Program and Co-Director of the TMS & Neuromodulation Clinic. He is Board Certified in Clinical Neurophysiology by the American Board of Clinical Neurophysiology and the American Board of Psychiatry and Neurology and Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is a pioneer in the application of computational modeling to the study of biomarker development using EEG in patients with depression and sleep disorders and application of biomarkers in treatment development clinical trials. He also has extensive experience in clinical and research personalization of therapies for the treatment of patients with mood disorders. He has been the principal investigator of more than 50 single-site and multi-site clinical trials.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-evaluated digital therapeutics into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Simon Lin, MD, MBA, is the Chief Research Information Officer at Nationwide Children’s Hospital. To transform the IT department at large organizations, Dr. Lin developed a formula for success: “Digital Leadership = Delivery x (Data + AI) x Ethics”. He has been a keynote speaker and panelist at a number of events, including CIO Summit, Becker’s Healthcare IT + Revenue Cycle, HIMSS Analytics, and IEEE Smart Health. He authored over 120 publications and edited five books.

As leader of Australia’s peak body for digital health, Dr Louise Schaper, is a passionate advocate for the transformation of healthcare, enabled by technology. As CEO and Fellow of the Australasian Institute of Digital Health she brings together world-class clinicians, researchers, innovators and organisations from across the biomedical, health and technology spectrum who are committed to the improvement of health outcomes enabled through innovative uses of technology and information. She is a facilitator, an innovator and a change agent who explores and leverages the convergence of people, systems and technologies in the transformation and future of health and medicine.

With a background as an occupational therapist, Louise has a PhD in technology acceptance among health professionals, is a graduate of Stanford’s Executive Leadership Program, a Certified Health Informatician, a Salzburg Global Seminar Fellow and a Fellow of the International Academy of Health Sciences Informatics.

Louise holds Adjunct Fellow positions at the University of Melbourne and Macquarie University and is a Board Director of Asthma Australia. Louise is an in-demand speaker and writes for academic and industry publications. She is host of the popular Dissecting Digital Health podcast, she is always online, and yes, she does have the coolest job!

Raj is a Medical Doctor, Professor, Technology Futurist, renowned Global Speaker, International Healthcare Volunteer & Entrepreneur -practicing ‘Healthcare Democratization’ by supporting disruptive Life sciences initiatives globally that can impact the planet

A globetrotter, Raj visited 7000+ Hospitals & Specialty Centers in 50+ countries, and continually served many Private Life Sciences Investment Committees, Venture Capital funded Consortium’s, Startup-Advisory Boards and many Government lead Digital Health wings across North America, Africa and Asia-Pacific regions.

With close to 2 decades of experience in Consumer Health, Connected Health , Wireless technologies, Devices & Platforms, Precision Medicine, Tele-Medicine, Digital Therapeutics and Startup’s Ecosystems, with specialization in Strategy & Leadership, Innovation & Corporate Development, Raj Pallapothu is currently heading ‘Bio 9 Ventures’, an international boutique firm offering services in the areas of Sovereign fund divestments in Healthcare

Sarah Jackson is Chief of Staff at Click Therapeutics, where she operates across business development, alliance management and strategy. In her role, Sarah actively seeks partnership and licensing opportunities, supports deal execution, and manages collaboration relationships and operations. Sarah holds a B.A. cum laude in Cognitive Neuroscience and Evolutionary Psychology from Harvard College.

Dr. Khandwalla has co-authored research papers on heart failure and has conducted research on mitral valve disease. He has an avid interest in complex valvular disease, as well as developing strategies for effective lifestyle modification. He is particularly interested in the use of mobile technology to help patients monitor and change their habits in order to reduce their cardiovascular risk.

Dr. John Krakauer leads all scientific discovery and validation for MindMaze following the acquisition in 2018 of the medtech company he founded called Neuro Motor Innovations.

In addition to serving as Chief Medical Advisor for MindMaze, John is also:

• John C. Malone Professor and Professor of Neurology, Neuroscience, and Physical Medicine and Rehabilitation at the Johns Hopkins University School of Medicine

• Co-director of the Brain, Learning, Animation, and Movement (BLAM) Lab

Valerie Sullivan brings significant experience in the pharma, digital health and pharma services industries to her role as President and CEO of etectRx. Innovative and forward thinking, she is passionate about creating meaningful, cost-effective solutions across the healthcare ecosystem by leveraging patient engagement and digital technology to support greater outcomes, more therapeutic impact and the potential to serve an unmet need.Prior to joining etectRx, she served as President of InVentiv Patient Access Solutions, a tech-enabled patient support services company. In addition, she served as Vice President and General Manager of the Patient Service Center at Pear Therapeutics, a program that she envisioned and built from the ground up. She began her career in healthcare working at Pfizer for over 15 years. Sullivan serves as an independent member on the board of directors at CareMetx and Two Labs Pharma Services, and is Chairman at the Group Insurance Commission, a quasi-state agency in the Commonwealth of MA. She is on faculty at Bentley University as an adjunct professor in the Management Department. She holds a Bachelor of Arts in Chemistry and Economics from College of the Holy Cross and an MBA in Finance and Marketing from Northeastern University.

Julia Strandberg serves as Chief Commercial Officer at Pear Therapeutics, responsible for crafting and implementing patient-, clinician-, and payer-centered strategies to accelerate the adoption of Prescription Digital Therapeutics (PDTs). She draws on extensive experience in developing and commercializing innovative medical technologies. From medical devices and RFID technologies, to consumer electronics, she has championed novel technologies and innovative business models to transform healthcare and advance the healthcare industry.

Prior to joining Pear, Julia served as Medtronic’s Vice President & General Manager for the Health Informatics & Monitoring division. She also has served as Vice President of Global Marketing for the Patient Monitoring franchise for Covidien. Julia joined Covidien in the Strategy & Portfolio group for Sleep Diagnostics and Therapy. She began her career at 3M Company, where she held multiple engineering and marketing positions in the Optical Systems and Track and Trace solutions division.

She earned her MBA from University of Minnesota, Carlson School of Management, and her undergraduate degree in Chemical Engineering at Purdue University.